{"id":58221,"date":"2023-10-15T01:06:04","date_gmt":"2023-10-14T23:06:04","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/avistone-announces-preclinical-results-for-ans014004-a-type-ii-c-met-tyrosine-kinase-inhibitor-tki-at-the-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\/"},"modified":"2023-10-15T01:06:04","modified_gmt":"2023-10-14T23:06:04","slug":"avistone-announces-preclinical-results-for-ans014004-a-type-ii-c-met-tyrosine-kinase-inhibitor-tki-at-the-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/avistone-announces-preclinical-results-for-ans014004-a-type-ii-c-met-tyrosine-kinase-inhibitor-tki-at-the-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\/","title":{"rendered":"Avistone Announces Preclinical Results for ANS014004, a Type II c-Met Tyrosine Kinase Inhibitor (TKI) at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics"},"content":{"rendered":"
\n

BEIJING, China–(BUSINESS WIRE)–Avistone Biotechnology Co., Ltd (\u201cAvistone\u201d or \u201cthe Company\u201d), a clinical-stage biotechnology company focused on precision oncology therapeutics, today announced results from its China and US IND enabling nonclinical studies for ANS014004 (\u201cANS01\u201d), a novel small-molecule type II c-Met tyrosine kinase inhibitor (TKI). The data were presented today (Poster# C145) at the AACR-NCI-EORTC meeting hosted by the American Association for Cancer Research (AACR), the National Cancer Institute (NCI), and the European Organisation for Research and Treatment of Cancer (EORTC) in Boston, Massachusetts USA.<\/p>\n

<\/a>
<\/a><\/p>\n

\nMesenchymal epithelial transition (MET) proto-oncogene receptor tyrosine kinase (RTK) is a cell surface receptor selective for hepatocyte growth factor (HGF), and is involved in embryogenesis regulation, wound healing, organ regeneration, angiogenesis, and immunomodulation. Aberrant MET oncogenic alterations include: MET exon 14 skipping (MET\u2206ex14) mutations; activating mutations in the kinase domain; MET gene amplification; MET fusions; and MET protein overexpression. These oncogenic alterations occur in a wide range of human solid cancers.<\/p>\n

\nPresently, type I c-Met inhibitors such as Capmatinib are used as monotherapies in patients with locally advanced or metastatic NSCLC with MET\u2206ex14 mutations. However, development of post-treatment resistance to type I c-Met inhibitors occurs clinically, including through acquired mutations in codons D1228 and Y1230. No drugs have been approved globally for MET alteration indications other than MET\u2206ex14 mutations. Next generation MET inhibitors are thus needed to treat patients harboring various MET oncogenic alterations beyond MET\u2206ex14, including post-treatment acquired mutations.<\/p>\n

\nOverall, the non-clinical studies of ANS014004 demonstrated it is a potent, orally-bioavailable type II c-Met inhibitor with activity against various pathogenetic MET alterations and with favorable absorption, distribution, pharmacokinetic, efficacy, and tolerability profiles in vivo. The molecule will enter Phase 1 clinical studies in both China and the US soon.<\/p>\n

\n\u201cAvistone is a science-driven, innovative biotechnology company committed to the discovery and clinical development of first-in-class and best-in-class drugs,\u201d said Dr. Hepeng Shi, Chairman, CEO, and Founder of Avistone. \u201cWe are proud to share these preclinical data for ANS014004 at this year\u2019s AACR-NCI-EORTC meeting for which has promise for patients with c-MET aberrations in NSCLC.\u201d<\/p>\n

\nElectronic copies of the poster presented at the AACR-NCI-EORTC annual meeting are available upon request.<\/p>\n

\nAbout Avistone Biotechnology Co. Ltd.<\/b><\/p>\n

\nAvistone is an oncology company focused on developing innovative therapies for patients with significant unmet medical needs globally. Avistone has an extensive pipeline of targeted therapies including two clinical-stage drug candidates and several ongoing programs in the pre-clinical development stage. The Company\u2019s lead asset is PLB1001, a small-molecule inhibitor that targets MET tyrosine kinase activity, including aberrant activity observed with METexon14 skipping (genetic) alterations in NSCLC tumors and in other solid tumors. The company’s second clinical asset is PLB1004, a potent inhibitor of EGFR tyrosine kinases (TKI), including aberrant activity observed with EGFR exon20 insertion (genetic) mutations in NSCLC tumors.<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia: David Chung (david.chung@avistonebio.com<\/a>)<\/b><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

BEIJING, China–(BUSINESS WIRE)–Avistone Biotechnology Co., Ltd (\u201cAvistone\u201d or \u201cthe Company\u201d), a clinical-stage biotechnology company focused on precision oncology therapeutics, today announced results from its China and US IND enabling nonclinical studies for ANS014004 (\u201cANS01\u201d), a novel small-molecule type II c-Met tyrosine kinase inhibitor (TKI). The data were presented today (Poster# C145) at the AACR-NCI-EORTC meeting … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-58221","6":"format-standard","7":"category-industry"},"yoast_head":"\nAvistone Announces Preclinical Results for ANS014004, a Type II c-Met Tyrosine Kinase Inhibitor (TKI) at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/avistone-announces-preclinical-results-for-ans014004-a-type-ii-c-met-tyrosine-kinase-inhibitor-tki-at-the-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Avistone Announces Preclinical Results for ANS014004, a Type II c-Met Tyrosine Kinase Inhibitor (TKI) at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"BEIJING, China–(BUSINESS WIRE)–Avistone Biotechnology Co., Ltd (\u201cAvistone\u201d or \u201cthe Company\u201d), a clinical-stage biotechnology company focused on precision oncology therapeutics, today announced results from its China and US IND enabling nonclinical studies for ANS014004 (\u201cANS01\u201d), a novel small-molecule type II c-Met tyrosine kinase inhibitor (TKI). The data were presented today (Poster# C145) at the AACR-NCI-EORTC meeting ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/avistone-announces-preclinical-results-for-ans014004-a-type-ii-c-met-tyrosine-kinase-inhibitor-tki-at-the-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-14T23:06:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20231014470634\/en\/1913808\/21\/Avistone_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avistone-announces-preclinical-results-for-ans014004-a-type-ii-c-met-tyrosine-kinase-inhibitor-tki-at-the-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avistone-announces-preclinical-results-for-ans014004-a-type-ii-c-met-tyrosine-kinase-inhibitor-tki-at-the-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Avistone Announces Preclinical Results for ANS014004, a Type II c-Met Tyrosine Kinase Inhibitor (TKI) at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics\",\"datePublished\":\"2023-10-14T23:06:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avistone-announces-preclinical-results-for-ans014004-a-type-ii-c-met-tyrosine-kinase-inhibitor-tki-at-the-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\\\/\"},\"wordCount\":499,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avistone-announces-preclinical-results-for-ans014004-a-type-ii-c-met-tyrosine-kinase-inhibitor-tki-at-the-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20231014470634\\\/en\\\/1913808\\\/21\\\/Avistone_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avistone-announces-preclinical-results-for-ans014004-a-type-ii-c-met-tyrosine-kinase-inhibitor-tki-at-the-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avistone-announces-preclinical-results-for-ans014004-a-type-ii-c-met-tyrosine-kinase-inhibitor-tki-at-the-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\\\/\",\"name\":\"Avistone Announces Preclinical Results for ANS014004, a Type II c-Met Tyrosine Kinase Inhibitor (TKI) at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avistone-announces-preclinical-results-for-ans014004-a-type-ii-c-met-tyrosine-kinase-inhibitor-tki-at-the-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avistone-announces-preclinical-results-for-ans014004-a-type-ii-c-met-tyrosine-kinase-inhibitor-tki-at-the-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20231014470634\\\/en\\\/1913808\\\/21\\\/Avistone_Logo.jpg\",\"datePublished\":\"2023-10-14T23:06:04+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avistone-announces-preclinical-results-for-ans014004-a-type-ii-c-met-tyrosine-kinase-inhibitor-tki-at-the-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avistone-announces-preclinical-results-for-ans014004-a-type-ii-c-met-tyrosine-kinase-inhibitor-tki-at-the-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avistone-announces-preclinical-results-for-ans014004-a-type-ii-c-met-tyrosine-kinase-inhibitor-tki-at-the-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20231014470634\\\/en\\\/1913808\\\/21\\\/Avistone_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20231014470634\\\/en\\\/1913808\\\/21\\\/Avistone_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/avistone-announces-preclinical-results-for-ans014004-a-type-ii-c-met-tyrosine-kinase-inhibitor-tki-at-the-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Avistone Announces Preclinical Results for ANS014004, a Type II c-Met Tyrosine Kinase Inhibitor (TKI) at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Avistone Announces Preclinical Results for ANS014004, a Type II c-Met Tyrosine Kinase Inhibitor (TKI) at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/avistone-announces-preclinical-results-for-ans014004-a-type-ii-c-met-tyrosine-kinase-inhibitor-tki-at-the-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\/","og_locale":"en_US","og_type":"article","og_title":"Avistone Announces Preclinical Results for ANS014004, a Type II c-Met Tyrosine Kinase Inhibitor (TKI) at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Pharma Trend","og_description":"BEIJING, China–(BUSINESS WIRE)–Avistone Biotechnology Co., Ltd (\u201cAvistone\u201d or \u201cthe Company\u201d), a clinical-stage biotechnology company focused on precision oncology therapeutics, today announced results from its China and US IND enabling nonclinical studies for ANS014004 (\u201cANS01\u201d), a novel small-molecule type II c-Met tyrosine kinase inhibitor (TKI). The data were presented today (Poster# C145) at the AACR-NCI-EORTC meeting ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/avistone-announces-preclinical-results-for-ans014004-a-type-ii-c-met-tyrosine-kinase-inhibitor-tki-at-the-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\/","og_site_name":"Pharma Trend","article_published_time":"2023-10-14T23:06:04+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20231014470634\/en\/1913808\/21\/Avistone_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/avistone-announces-preclinical-results-for-ans014004-a-type-ii-c-met-tyrosine-kinase-inhibitor-tki-at-the-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/avistone-announces-preclinical-results-for-ans014004-a-type-ii-c-met-tyrosine-kinase-inhibitor-tki-at-the-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Avistone Announces Preclinical Results for ANS014004, a Type II c-Met Tyrosine Kinase Inhibitor (TKI) at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics","datePublished":"2023-10-14T23:06:04+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/avistone-announces-preclinical-results-for-ans014004-a-type-ii-c-met-tyrosine-kinase-inhibitor-tki-at-the-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\/"},"wordCount":499,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/avistone-announces-preclinical-results-for-ans014004-a-type-ii-c-met-tyrosine-kinase-inhibitor-tki-at-the-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20231014470634\/en\/1913808\/21\/Avistone_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/avistone-announces-preclinical-results-for-ans014004-a-type-ii-c-met-tyrosine-kinase-inhibitor-tki-at-the-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\/","url":"https:\/\/pharma-trend.com\/en\/avistone-announces-preclinical-results-for-ans014004-a-type-ii-c-met-tyrosine-kinase-inhibitor-tki-at-the-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\/","name":"Avistone Announces Preclinical Results for ANS014004, a Type II c-Met Tyrosine Kinase Inhibitor (TKI) at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/avistone-announces-preclinical-results-for-ans014004-a-type-ii-c-met-tyrosine-kinase-inhibitor-tki-at-the-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/avistone-announces-preclinical-results-for-ans014004-a-type-ii-c-met-tyrosine-kinase-inhibitor-tki-at-the-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20231014470634\/en\/1913808\/21\/Avistone_Logo.jpg","datePublished":"2023-10-14T23:06:04+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/avistone-announces-preclinical-results-for-ans014004-a-type-ii-c-met-tyrosine-kinase-inhibitor-tki-at-the-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/avistone-announces-preclinical-results-for-ans014004-a-type-ii-c-met-tyrosine-kinase-inhibitor-tki-at-the-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/avistone-announces-preclinical-results-for-ans014004-a-type-ii-c-met-tyrosine-kinase-inhibitor-tki-at-the-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20231014470634\/en\/1913808\/21\/Avistone_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20231014470634\/en\/1913808\/21\/Avistone_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/avistone-announces-preclinical-results-for-ans014004-a-type-ii-c-met-tyrosine-kinase-inhibitor-tki-at-the-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Avistone Announces Preclinical Results for ANS014004, a Type II c-Met Tyrosine Kinase Inhibitor (TKI) at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/58221","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=58221"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/58221\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=58221"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=58221"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=58221"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}